

Gaby Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1229053/publications.pdf>

Version: 2024-02-01

97
papers

6,307
citations

101496

36
h-index

66879

78
g-index

108
all docs

108
docs citations

108
times ranked

8725
citing authors

#	ARTICLE	IF	CITATIONS
1	Multifaceted roles of IL-38 in inflammation and cancer. <i>Cytokine</i> , 2022, 151, 155808.	1.4	12
2	IL-38 orchestrates proliferation and differentiation in human keratinocytes. <i>Experimental Dermatology</i> , 2022, 31, 1699-1711.	1.4	12
3	Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease. <i>Rheumatology</i> , 2021, 60, 3451-3460.	0.9	6
4	IL-1 Family Antagonists in Mouse and Human Skin Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 652846.	2.2	41
5	IL-38 Ablation Reduces Local Inflammation and Disease Severity in Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2021, 206, 1058-1066.	0.4	13
6	Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation Syndrome. <i>Journal of Immunology</i> , 2020, 205, 1167-1175.	0.4	13
7	Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-1 α . <i>Journal of Immunology</i> , 2020, 204, 967-979.	0.4	8
8	Interleukin-33 Signaling Controls the Development of Iron-Recycling Macrophages. <i>Immunity</i> , 2020, 52, 782-793.e5.	6.6	37
9	P157...Radioresistant and radiosensitive cells contribute to IL-18BP production in a model of macrophage activation syndrome. , 2019, , .		0
10	P069...Constitutive overexpression of interleukin 38 has a negative impact on human NHK keratinocyte fitness. , 2019, , .		0
11	P097...Intracellular interleukin-1 receptor antagonist released upon cell death acts as an alarmin inhibitor in aldera cream-induced psoriasis-like skin inflammation. , 2019, , .		0
12	SAT0005...DETECTION OF HIGHLY EXPANDED T CELL CLONES IN THE PERIPHERAL BLOOD OF AT RISK INDIVIDUALS FOR RHEUMATOID ARTHRITIS BEFORE THE CLINICAL ONSET OF THE DISEASE. , 2019, , .		0
13	Interleukin-38 interacts with destrin/actin-depolymerizing factor in human keratinocytes. <i>PLoS ONE</i> , 2019, 14, e0225782.	1.1	16
14	Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. <i>Blood</i> , 2018, 131, 1430-1441.	0.6	102
15	O025...Unopposed interleukin 18 signalling leads to severe toll like receptor 9-induced macrophage activation syndrome in mice. , 2018, , .		0
16	The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. <i>PLoS ONE</i> , 2018, 13, e0194667.	1.1	31
17	Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses. <i>Journal of Immunology</i> , 2017, 198, 2916-2926.	0.4	14
18	IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1304-1312.	0.5	101

#	ARTICLE	IF	CITATIONS
19	02.11â€¦IL-38 is not involved in the modulation of imq-induced skin inflammation. , 2017, , .		0
20	A7.13â€¦Distinct expression of IL-36Î±, Î², Î³ and their antagonists IL-36RA and IL-38 in psoriasis, rheumatoid arthritis (RA) and crohnâ€™s disease (CD). Annals of the Rheumatic Diseases, 2016, 75, A60.3-A61.	0.5	0
21	IL-36â€™Induced Toxicity in Neonatal Mice Involves TNF-Î± Production by Liver Myeloid Cells. Journal of Immunology, 2016, 197, 2239-2249.	0.4	7
22	A10.02â€¦Deficiency in IL-1 receptor type 2 aggravates K/BXN serum transfer-induced arthritis in mice, but has no effect in endotoxemia. Annals of the Rheumatic Diseases, 2016, 75, A73.1-A73.	0.5	0
23	Distinct expression of interleukin (IL)-36Î±, Î² and Î³, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clinical and Experimental Immunology, 2016, 184, 159-173.	1.1	214
24	Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. Cytokine, 2016, 84, 88-98.	1.4	70
25	Interleukin-33 and RANK-L Interplay in the Alveolar Bone Loss Associated to Periodontitis. PLoS ONE, 2016, 11, e0168080.	1.1	42
26	A5.12â€¦Atherosclerosis severity is independent of endogenous IL-33 signalling. Annals of the Rheumatic Diseases, 2015, 74, A51.3-A52.	0.5	0
27	Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection. PLoS ONE, 2015, 10, e0126058.	1.1	33
28	Atherosclerosis severity is not affected by a deficiency in ILâ€³3/ST2 signaling. Immunity, Inflammation and Disease, 2015, 3, 239-246.	1.3	18
29	The interleukin (IL)-1 cytokine family â€™ Balance between agonists and antagonists in inflammatory diseases. Cytokine, 2015, 76, 25-37.	1.4	385
30	Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33â€™Overexpressing CMV/IL33 Mice. Journal of Immunology, 2015, 194, 750-760.	0.4	26
31	Immune-mediated experimental arthritis in IL-33 deficient mice. Cytokine, 2014, 69, 68-74.	1.4	20
32	The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Research and Therapy, 2013, 15, R38.	1.6	52
33	Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Research and Therapy, 2013, 15, R13.	1.6	33
34	Reply to Xie et al. about the article â€™Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritisâ€™. Joint Bone Spine, 2013, 80, 117-118.	0.8	1
35	Endogenous IL-1Î± is a chromatin-associated protein in mouse macrophages. Cytokine, 2013, 63, 135-144.	1.4	29
36	Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. Journal of Leukocyte Biology, 2013, 94, 791-802.	1.5	47

#	ARTICLE	IF	CITATIONS
37	Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 281-287.	0.5	14
38	IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. <i>Blood</i> , 2012, 120, 3478-3487.	0.6	195
39	OO34 Expression of the decoy type 2 interleukin-1 receptor in mouse and its putative role in inflammation. <i>Cytokine</i> , 2012, 59, 513.	1.4	0
40	Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitis. <i>European Journal of Immunology</i> , 2012, 42, 1294-1303.	1.6	16
41	Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Joint Bone Spine</i> , 2012, 79, 32-37.	0.8	81
42	Interleukin-33 biology with potential insights into human diseases. <i>Nature Reviews Rheumatology</i> , 2011, 7, 321-329.	3.5	184
43	IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. <i>Cytokine</i> , 2011, 53, 347-354.	1.4	52
44	IL-36R ligands are potent regulators of dendritic and T cells. <i>Blood</i> , 2011, 118, 5813-5823.	0.6	271
45	Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3354-3363.	6.7	5
46	Inflammation and autoimmune responses are independent of peripheral MHC class II expression driven by CIITA pIV in collagen induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A25-A25.	0.5	0
47	Interleukin 33 expression in human arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A14-A15.	0.5	0
48	The mouse interleukin (IL)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. <i>Journal of Leukocyte Biology</i> , 2011, 91, 119-125.	1.5	52
49	Inhibition of osteoclast differentiation by the interleukin (IL)-1 family cytokine IL-33. <i>IBMS BoneKEy</i> , 2011, 8, 415-419.	0.1	0
50	IL-1 pathways in inflammation and human diseases. <i>Nature Reviews Rheumatology</i> , 2010, 6, 232-241.	3.5	689
51	Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. <i>Arthritis and Rheumatism</i> , 2010, 62, 452-462.	6.7	37
52	Expression and function of the NALP3 inflammasome in rheumatoid synovium. <i>Immunology</i> , 2010, 129, 178-185.	2.0	85
53	Distinct Roles of Hepatocyte- and Myeloid Cell-Derived IL-1 Receptor Antagonist during Endotoxemia and Sterile Inflammation in Mice. <i>Journal of Immunology</i> , 2010, 185, 2516-2524.	0.4	21
54	Interleukin-33 Is Biologically Active Independently of Caspase-1 Cleavage. <i>Journal of Biological Chemistry</i> , 2009, 284, 19420-19426.	1.6	226

#	ARTICLE	IF	CITATIONS
55	Adaptive Immune Response in JAM-C-Deficient Mice: Normal Initiation but Reduced IgG Memory. <i>Journal of Immunology</i> , 2009, 182, 4728-4736.	0.4	12
56	Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. <i>Joint Bone Spine</i> , 2009, 76, 424-426.	0.8	76
57	Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 738-749.	6.7	294
58	L'anakinra est une alternative possible dans le traitement et la prévention des crises de pseudogoutte au stade terminal d'une insuffisance rénale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009, 76, 715-717.	0.0	0
59	Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice. <i>Arthritis Research and Therapy</i> , 2009, 11, R72.	1.6	45
60	Mutations in the IL1RN locus lead to autoinflammation. <i>Nature Reviews Rheumatology</i> , 2009, 5, 480-482.	3.5	10
61	IL-1, IL-18, and IL-33 families of cytokines. <i>Immunological Reviews</i> , 2008, 223, 20-38.	2.8	770
62	The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. <i>Cytokine</i> , 2008, 42, 358-364.	1.4	160
63	67 Biological role of hepatocyte-derived interleukin-1 receptor antagonist in a model of systemic inflammation. <i>Cytokine</i> , 2008, 43, 252.	1.4	0
64	68 Biological role of myeloid cell-derived interleukin-1 receptor antagonist in collagen-induced arthritis. <i>Cytokine</i> , 2008, 43, 252.	1.4	0
65	Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. <i>Cytokine</i> , 2007, 40, 216-225.	1.4	285
66	Expression and function of junctional adhesion molecule-C in human and experimental arthritis. <i>Arthritis Research and Therapy</i> , 2007, 9, R65.	1.6	36
67	IL-33: a novel cytokine with proinflammatory properties. <i>Arthritis Research and Therapy</i> , 2007, 9, P9.	1.6	0
68	Type I IL-1 Receptor Mediates IL-1 and Intracellular IL-1 Receptor Antagonist Effects in Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1938-1946.	0.3	22
69	Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms. <i>Journal of the American Association for Laboratory Animal Science</i> , 2007, 46, 21-4.	0.6	9
70	The role of leptin in innate and adaptive immune responses. <i>Arthritis Research and Therapy</i> , 2006, 8, 217.	1.6	98
71	The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. <i>Arthritis Research and Therapy</i> , 2006, 8, R80.	1.6	105
72	The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1 β and TNF α . <i>Inflammation Research</i> , 2006, 55, 469-475.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Practice and Research in Clinical Rheumatology, 2006, 20, 879-896.	1.4	144
74	Leukocyte migration to rheumatoid joints: Enzymes take over. Arthritis and Rheumatism, 2006, 54, 2707-2710.	6.7	15
75	Indirect Effects of Leptin Receptor Deficiency on Lymphocyte Populations and Immune Response in <i>db/db</i> Mice. Journal of Immunology, 2006, 177, 2899-2907.	0.4	75
76	Pre-interleukin-1 β expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icL-1Ra1). Cytokine, 2005, 31, 153-160.	1.4	28
77	Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis and Rheumatism, 2004, 50, 4051-4059.	6.7	69
78	Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice. Arthritis Research, 2004, 6, R256.	2.0	54
79	The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Research, 2004, 6, R181.	2.0	17
80	Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. European Journal of Immunology, 2003, 33, 434-440.	1.6	29
81	Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Research, 2002, 4, 226.	2.0	44
82	Primary human articular chondrocytes, dedifferentiated chondrocytes, and synoviocytes exhibit differential responsiveness to interleukin-4: Correlation with the expression pattern of the common receptor gamma chain. Journal of Cellular Physiology, 2002, 192, 93-101.	2.0	18
83	Species-specific mechanisms control the activity of the Pit1/PIT1 phosphate transporter gene promoter in mouse and human. Gene, 2001, 279, 49-62.	1.0	6
84	Stimulation of Sodium-Dependent Phosphate Transport and Signaling Mechanisms Induced by Basic Fibroblast Growth Factor in MC3T3-E1 Osteoblast-like Cells. Journal of Bone and Mineral Research, 2000, 15, 95-102.	3.1	59
85	Evidence for the Involvement of Two Pathways in Activation of Extracellular Signal-Regulated Kinase (Erk) and Cell Proliferation by Gi and Gq Protein-Coupled Receptors in Osteoblast-Like Cells. Journal of Bone and Mineral Research, 2000, 15, 1697-1706.	3.1	49
86	Positive and Negative Control of the Expression of Parathyroid Hormone (PTH)/PTH-Related Protein Receptor Via Proximal Promoter P3 in Human Osteoblast-Like Cells ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3376-3382.	1.8	10
87	Transforming Growth Factor- β 2 Stimulates Inorganic Phosphate Transport and Expression of the Type III Phosphate Transporter Glvr-1 in Chondrogenic ATDC5 Cells*. Endocrinology, 2000, 141, 2236-2243.	1.4	60
88	Structure of the murine Pit1 phosphate transporter/retrovirus receptor gene and functional characterization of its promoter region. Gene, 2000, 244, 35-45.	1.0	6
89	Transforming Growth Factor- β Stimulates Inorganic Phosphate Transport and Expression of the Type III Phosphate Transporter Glvr-1 in Chondrogenic ATDC5 Cells. Endocrinology, 2000, 141, 2236-2243.	1.4	21
90	Regulation of Alkaline Phosphatase Activity by p38 MAP Kinase in Response to Activation of Gi Protein-Coupled Receptors by Epinephrine in Osteoblast-Like Cells ¹ . Endocrinology, 1999, 140, 3177-3182.	1.4	97

#	ARTICLE	IF	CITATIONS
91	Characterization of the human Glvr-1 phosphate transporter/retrovirus receptor gene and promoter region. <i>Gene</i> , 1999, 226, 25-33.	1.0	12
92	Regulation of Alkaline Phosphatase Activity by p38 MAP Kinase in Response to Activation of Gi Protein-Coupled Receptors by Epinephrine in Osteoblast-Like Cells. <i>Endocrinology</i> , 1999, 140, 3177-3182.	1.4	32
93	Sequence and activity of parathyroid hormone/parathyroid hormone-related protein receptor promoter region in human osteoblast-like cells. <i>Gene</i> , 1998, 218, 49-56.	1.0	19
94	Expression of a Newly Identified Phosphate Transporter/Retrovirus Receptor in Human SaOS-2 Osteoblast-Like Cells and Its Regulation by Insulin-Like Growth Factor I ¹ . <i>Endocrinology</i> , 1997, 138, 5202-5209.	1.4	87
95	Mechanism of the Mitogenic Effect of Fluoride on Osteoblast-like Cells: Evidences for a G Protein-Dependent Tyrosine Phosphorylation Process. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1975-1983.	3.1	52
96	Expression of a Newly Identified Phosphate Transporter/Retrovirus Receptor in Human SaOS-2 Osteoblast-Like Cells and Its Regulation by Insulin-Like Growth Factor I. <i>Endocrinology</i> , 1997, 138, 5202-5209.	1.4	34
97	<i>Trypanosoma cruzi</i> heat-shock protein 90 can functionally complement yeast. <i>Molecular and Biochemical Parasitology</i> , 1995, 70, 199-202.	0.5	24